 Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 6 | 6 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 5 | 5 | | 2006 | 1 | 3 | 4 | | 2007 | 0 | 6 | 6 | | 2008 | 3 | 8 | 11 | | 2009 | 1 | 14 | 15 | | 2010 | 1 | 15 | 16 | | 2011 | 2 | 13 | 15 | | 2012 | 2 | 23 | 25 | | 2013 | 2 | 19 | 21 | | 2014 | 0 | 19 | 19 | | 2015 | 3 | 27 | 30 | | 2016 | 5 | 25 | 30 | | 2017 | 3 | 41 | 44 | | 2018 | 6 | 32 | 38 | | 2019 | 1 | 30 | 31 | | 2020 | 1 | 34 | 35 | | 2021 | 2 | 18 | 20 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 3 | 3 | | 2024 | 8 | 20 | 28 | | 2025 | 0 | 35 | 35 | | 2026 | 0 | 10 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Lin HK, Blake DA, Freeman R, Chen Y, Kim J, Johnson AM, Wells K, Mudigonda A, Liu W, Yadav P, Zeng F, Muhuri A, Min K, Sarkar S, Wang Y, Goyal S, Roberts RC, Christensen E, Ward AB, Heller B, Chun P, Dougan J, Porter CC, Barwick BG, Paulos CM, Yang L, Patgiri A, Thomas SN, Waller EK, Rafiq S. Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models. Sci Transl Med. 2026 Jul 22; 18(859):eadt9565.
-
Favours E, Tang H, Wong P, Ghilu S, Del Pozo V, Mironova E, Chen Y, Stearns T, Neuhauser S, Earley EJ, Erickson SW, Kwon JY, Jocoy EL, Groff D, Krytska K, Tsang M, Teicher BA, Mossé YP, Kolb EA, Hav M, Loo D, Houghton PJ, Bult CJ, Gorlick RG, Maris JM, Smith MA, Kurmasheva RT. Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors. Clin Cancer Res. 2026 Jul 17; 32(14):3031-3042.
-
Yamamoto TM, Iwanaga R, Woodruff ER, Elder AM, Petkov A, Nurmemmedov E, Eisenmesser E, Reigan P, Bitler BG, Brubaker LW. Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. Mol Cancer Ther. 2026 Jul 02; 25(7):1130-1143.
-
Garcia C, Lyons KU, Contreras JG, Liu T, Donnelly AJ, Novak AJ, Argabright A, Anderson C, Grier A, Smith S, Michlin J, Olusoji J, Mikeska RG, Zhou X, Geng H, Rahkola JT, Patel HN, Jacot JG, Müschen M, D'Alessandro A, Dick JE, Iacobucci I, Mullighan CG, Reisz JA, Phang T, Eric Kohler M, Witkowski MT. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia. 2026 Aug; 40(8):1763-1777.
-
Duffy JT, Martin-Regalado A, Haupt BE, Pogue JR, Thakur A, Cota MF, Zannikou M, Misener S, Krymskaya VP, McCortney K, Miska J, Horbinski C, Simberg D, Lesniak MS, James CD, Stupp R, Balyasnikova IV. Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. Adv Sci (Weinh). 2026 Jun; 13(35):e22391.
-
Figueroa V, Coianis MI, Sahores A, Pataccini G, Abba MC, Elía A, May M, Vanzulli SI, Martínez Vázquez P, Burruchaga J, Torres F, Sartorius CA, Lanari C, Lamb CA. Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. Br J Cancer. 2026 Jun; 134(11):1671-1682.
-
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ. Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer Res. 2026 Apr 02; 86(7):1605-1621.
-
Cardus O, Mañé Pujol J, de Daniel A, Moreno DF, Oliveira TGM, Battram AM, Salsench SV, Perez-Amill L, Llobregat H, Carpio Mármol J, Martin-Antonio B, Oliver-Caldes A, Munárriz D, Juan M, Urbano-Ispizua A, Rodríguez-Lobato LG, Fernández de Larrea C. Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. J Immunother Cancer. 2026 Mar 03; 14(3).
-
Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, Kogiso M, Stephan C, Alton G, Stein G, Beaton G, Kesari S, Neuhauser S, Stearns T, Chuang J, Jocoy EL, Bult CJ, Teicher B, Smith MA, Li XN. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. Int J Mol Sci. 2026 Feb 04; 27(3).
-
Dela Cruz FS, Stewart EA, Surdez D, Daley JD, Soragni A, Tomazou EM, Alvarez-Perez J, Feinberg TY, Amatruda JF, Ganapathi SS, Ohm JE, Heske CM, Cohen-Gogo S, Pesic D, Nash JO, Shlien A, Roundhill EA, Burchill SA, Crompton BD, Lawlor ER, Loeb DM, Delattre O, Mora J, Scotlandi K, Reed DR, Grohar PJ, Grünewald TGP, Kovar H, Bailey KM. Advancing Preclinical Biology for Ewing Sarcoma: An International Effort. Mol Cancer Ther. 2026 Jan 02; 25(1):48-70.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|